Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
981 to 1,000 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. | J Med Chem | 2022 | 36410047 | PubTator, text mining | PubMed |
| Circular RNAs in organ injury: recent development. | J Transl Med | 2022 | 36401311 | PubTator, text mining | PubMed |
| Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. | Front Oncol | 2022 | 36387095 | PubTator, text mining | PubMed |
| Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. | Mem Inst Oswaldo Cruz | 2022 | 36383784 | PubTator, text mining | PubMed |
| ΔNp63α transcriptionally represses p53 target genes involved in the radiation-induced DNA damage response : ΔNp63α may cause genomic instability in epithelial stem cells. | Radiat Oncol | 2022 | 36380314 | PubTator, text mining | PubMed |
| Molecular glue CELMoD compounds are regulators of cereblon conformation. | Science | 2022 | 36378961 | PubTator, text mining | PubMed |
| Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy. | EBioMedicine | 2022 | 36375317 | PubTator, text mining | PubMed |
| Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon. | Biochem Biophys Res Commun | 2022 | 36375252 | PubTator, text mining | PubMed |
| Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance. | J Clin Med | 2022 | 36362718 | PubTator, text mining | PubMed |
| The E3 Ligases in Cervical Cancer and Endometrial Cancer. | Cancers (Basel) | 2022 | 36358773 | PubTator, text mining | PubMed |
| Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma? | Cancers (Basel) | 2022 | 36358759 | PubTator, text mining | PubMed |
| Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma. | Cancers (Basel) | 2022 | 36358696 | PubTator, text mining | PubMed |
| The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. | Expert Rev Proteomics | 2022 | 36342226 | PubTator, text mining | PubMed |
| A pan-cancer analysis of copper homeostasis-related gene lipoyltransferase 1: Its potential biological functions and prognosis values. | Front Genet | 2022 | 36330439 | PubTator, text mining | PubMed |
| Molecular and Structural Characterization of Lenalidomide-Mediated Sequestration of eIF3i. | ACS Chem Biol | 2022 | 36325969 | PubTator, text mining | PubMed |
| A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs. | J Med Chem | 2022 | 36323630 | PubTator, text mining | PubMed |
| Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation. | Cell Chem Biol | 2022 | 36323324 | PubTator, text mining | PubMed |
| Copy number variant analysis for syndromic congenital heart disease in the Chinese population. | Hum Genomics | 2022 | 36316717 | PubTator, text mining | PubMed |
| Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. | Front Immunol | 2022 | 36311747 | PubTator, text mining | PubMed |
| Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor. | Eur J Med Chem | 2022 | 36306539 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=50